Gemcitabine in Combination With Cisplatin as Neoadjuvant NSCLC Chemotherapy

• Status: Completed
• Trial end date: 2006-02-01
• Target enrollment: 0
• Participant gender: All

Summary

To evaluate the clinical response rate of neoadjuvant chemotherapy with gemcitabine and cisplatin in patients with operable NSCLC

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Eli Lilly and Company
• Treatments: Cisplatin; Gemcitabine

Criteria

Inclusion Criteria:

• histologic or cytologic diagnosis of operable non-small cell lung cancer (IB-IIIA)

• no prior chemotherapy

• WHO criteria for disease status assessment

Exclusion Criteria:

• Concurrent administration of any other tumor therapy

• pregnant or breast feeding

• serious concomitant disorders